Fate Therapeutics has advanced multiple novel candidate products into human clinical trials under Investigational New Drug applications cleared by the FDA, but it has not yet secured final commercial marketing approval for any standalone pharmaceutical drug product. As a clinical-stage biopharmaceutical enterprise, its pipeline consists of investigational off-the-shelf natural killer cell and T-cell immunotherapies undergoing rigorous Phase 1 and Phase 2 clinical evaluation. Achieving final FDA approval requires successfully navigating extensive multi-phase clinical trials to prove safety and efficacy, meaning the company remains in a developmental stage focused on scientific milestones rather than commercial product sales.